NYSE:NVS

Novartis SEC Filings & 10K Form

$92.37
+0.18 (+0.20 %)
(As of 07/30/2021 11:39 AM ET)
Add
Compare
Today's Range
$92.31
$92.91
50-Day Range
$88.02
$94.15
52-Week Range
$77.04
$98.52
Volume28,241 shs
Average Volume1.89 million shs
Market Capitalization$211.41 billion
P/E Ratio23.38
Dividend Yield2.26%
Beta0.55

Novartis (NYSE:NVS) SEC Filings

DateFilerForm TypeView
07/21/2021
5:55 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/28/2021
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/01/2021
5:03 AM
Novartis (Filer)
Form SD
Specialized Disclosure Report  
04/27/2021
6:30 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/23/2021
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/22/2021
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/09/2021
8:18 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/05/2021
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/29/2021
1:05 PM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/26/2021
7:59 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/26/2021
7:58 AM
Novartis (Filer)
Form IRANNOTICE
01/26/2021
7:56 AM
Novartis (Filer)
Form 20-F
Registration statement / Annual report / Transition report  
12/21/2020
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/24/2020
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/19/2020
4:23 PM
Novartis (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
10/27/2020
6:04 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/16/2020
7:34 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/23/2020
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/01/2020
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/20/2020
1:21 PM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/19/2020
3:31 PM
Novartis (Filed by)
XOMA Corp (Subject)
Form SC 13G/A
08/17/2020
1:15 PM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/14/2020
3:32 PM
Cellular Biomedicine Group, Inc. (Issuer)
Novartis (Reporting)
NOVARTIS PHARMA AG (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
07/21/2020
8:38 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/16/2020
3:53 PM
Novartis (Reporting)
NOVARTIS PHARMA AG (Reporting)
Poseida Therapeutics, Inc. (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/13/2020
5:02 AM
Novartis (Reporting)
NOVARTIS PHARMA AG (Reporting)
Poseida Therapeutics, Inc. (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
07/02/2020
6:44 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/25/2020
6:15 PM
Akouos, Inc. (Issuer)
Akouos, Inc. (Issuer)
Novartis (Reporting)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
06/25/2020
2:17 PM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/18/2020
8:16 PM
Forma Therapeutics Holdings, Inc., (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
06/17/2020
4:47 PM
Galera Therapeutics, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/16/2020
7:56 PM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/12/2020
5:33 PM
Galera Therapeutics, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2020
7:02 PM
Galera Therapeutics, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2020
4:36 PM
Galera Therapeutics, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/01/2020
7:53 AM
Novartis (Filer)
Form SD
Specialized Disclosure Report  
05/12/2020
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/28/2020
6:58 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/02/2020
6:50 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/27/2020
9:15 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/27/2020
9:15 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/19/2020
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/28/2020
7:29 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/12/2020
2:34 PM
Novartis (Filer)
Novartis Capital CORP (Filer)
Form 424B5
02/11/2020
6:57 AM
Novartis (Filer)
Novartis Capital CORP (Filer)
Form 424B5
01/31/2020
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/30/2020
9:40 AM
Novartis (Filer)
Novartis Capital CORP (Filer)
Form F-3ASR
01/29/2020
8:13 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/29/2020
8:07 AM
Novartis (Filer)
Form IRANNOTICE
01/29/2020
7:51 AM
Novartis (Filer)
Form 20-F
Registration statement / Annual report / Transition report  
01/06/2020
5:29 AM
MEDICINES CO /DE (Subject)
Novartis (Filed by)
Form SC TO-T/A
01/06/2020
5:10 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/23/2019
7:01 AM
MEDICINES CO /DE (Subject)
Novartis (Filed by)
Form SC TO-T/A
12/19/2019
7:02 AM
MEDICINES CO /DE (Subject)
Novartis (Filed by)
Form SC TO-T/A
12/16/2019
5:10 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/05/2019
6:58 AM
MEDICINES CO /DE (Subject)
Novartis (Filed by)
Form SC TO-T
12/05/2019
5:20 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/25/2019
3:52 PM
MEDICINES CO /DE (Subject)
Novartis (Filed by)
Form SC TO-C
11/25/2019
6:32 AM
MEDICINES CO /DE (Subject)
Novartis (Filed by)
Form SC TO-C
11/25/2019
5:30 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/15/2019
4:03 PM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/12/2019
3:15 PM
Galera Therapeutics, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/06/2019
4:23 PM
Galera Therapeutics, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
11/01/2019
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/30/2019
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/22/2019
7:08 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/08/2019
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/02/2019
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/30/2019
5:30 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/17/2019
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/30/2019
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/29/2019
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/18/2019
8:41 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/01/2019
1:20 PM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/07/2019
6:21 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/31/2019
9:00 AM
Novartis (Filer)
Form SD
Specialized Disclosure Report  
05/30/2019
8:27 PM
BICYCLE THERAPEUTICS plc (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/28/2019
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/24/2019
1:35 PM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/24/2019
1:23 PM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/22/2019
8:43 PM
BICYCLE THERAPEUTICS Ltd (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
05/09/2019
5:06 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/29/2019
4:23 PM
Aerpio Pharmaceuticals, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/24/2019
6:03 PM
Aerpio Pharmaceuticals, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/24/2019
12:09 PM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/15/2019
8:26 PM
Aerpio Pharmaceuticals, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/10/2019
5:26 PM
Aerpio Pharmaceuticals, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/05/2019
4:14 PM
Aerpio Pharmaceuticals, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/02/2019
7:23 PM
AILERON THERAPEUTICS INC (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/02/2019
7:09 PM
Aerpio Pharmaceuticals, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/28/2019
4:16 PM
Aerpio Pharmaceuticals, Inc. (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/27/2019
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/22/2019
7:20 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/15/2019
4:25 PM
AILERON THERAPEUTICS INC (Issuer)
Novartis (Reporting)
Novartis Bioventures Ltd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/14/2019
6:56 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/26/2019
5:00 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/14/2019
3:02 PM
Intellia Therapeutics, Inc. (Issuer)
Novartis (Reporting)
Novartis Institutes for BioMedical Research, Inc. (Reporting)
Form 5
Annual statement of changes in beneficial ownership of securities  
01/30/2019
7:09 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/30/2019
6:31 AM
Novartis (Filer)
Form IRANNOTICE
01/30/2019
6:31 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
This page was last updated on 7/30/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.